A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T76756 | Parsatuzumab | 1312797-14-0 | 98% |
|
Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.Parsatuzumab selectively inhibits the interac... | ||||
T76758 | Rilotumumab | 872514-65-3 | 98% |
Rilotumumab
|
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and ... | ||||
T76760 | Sifalimumab | 1006877-41-3 | 98% |
Sifalimumab
|
Sifalimumab (MEDI-545) is a monoclonal antibody that targets IFNα and suppresses abnormal immune activity by binding to interferon-alpha.Sifalimumab is used for ... | ||||
T76761 | Olaratumab | 1024603-93-7 | 98% |
Olaratumab
|
Olaratumab(IMC-3G3) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has antitumor effects and can be us... | ||||
T76763 | Teplizumab | 876387-05-2 | 98% |
|
Teplizumab (MGA-031) is a humanized monoclonal antibody against CD3 that slows the loss of beta cell function.Teplizumab is used to treat type 1 diabetes. | ||||
T76766 | Mirvetuximab | 1453084-36-0 | 98% |
Mirvetuximab
|
Mirvetuximab (M9346A) is a novel monoclonal antibody targeting anti-FOLR1 (folate receptor 1) with folate receptor α (FRα). Mirvetuximab soravtansine is often co... | ||||
T76769 | Indusatumab | 1497400-26-6 | 98% |
Indusatumab
|
Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody that can be used to synthesize antibody-drug conjugate. | ||||
T76773 | Rolinsatamab | 2095467-30-2 | 98% |
Rolinsatamab
|
Rolinsatamab is a fully humanized selective monoclonal antibody that is a potent dual inhibitor of IL-4 and IL-13. Rolinsatamab chimeric antigen receptor sequenc... | ||||
T76774 | Ponsegromab | 2368950-15-4 | 98% |
Ponsegromab
|
Ponsegromab (PF 06946860) is a selective and effective humanized anti-GDF15 antibody inhibitor. Ponsegromab has anti-cachexic activity by binding to GDF15 to pre... | ||||
T76775 | Fezakinumab | 1007106-86-6 | 98% |
Fezakinumab
|
Fezakinumab is a potent monoclonal antibody to interleukin-22 (IL-22). Fezakinumab can be used to study immune system diseases and inflammation-related condition... | ||||
T76776 | Emactuzumab | 1448221-67-7 | 98% |
|
Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumo... | ||||
T76777 | Bermekimab | 1401965-15-8 | 98% |
|
Bermekimab (MABp1) is a humanized monoclonal antibody against interleukin-1α (IL-1α).Bermekimab has potential anti-inflammatory activity to prevent skin inflamma... | ||||
T76778 | Risankizumab | 1612838-76-2 | 98% |
|
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. Risankizumab inhibits IL-17 production induced by hu... | ||||
T76780 | Onartuzumab | 1133766-06-9 | 98% |
|
Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.Onartuzumab has antitumor activity with inhibitory effects on HGF b... | ||||
T76781 | Itolizumab | 1116433-11-4 | 98% |
Itolizumab
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that humanizes the extracellular SRCR distal domain 1 of CD6. Itol... | ||||
T76782 | Mogamulizumab | 1159266-37-1 | 98% |
Mogamulizumab
|
Mogamulizumab (KW-0761) is a monoclonal antibody against T cell CC chemokine receptor 4. Mogamulizumab has anticancer activity, eliminating tumor cells through a... | ||||
T76784 | Tildrakizumab | 1326244-10-3 | 98% |
Tildrakizumab
|
Tildrakizumab (SCH 900222) is a potent humanized monoclonal antibody against IL-23 (p19 subunit). Tildrakizumab targets single-stranded IL-23 with a Kd value of ... | ||||
T76788 | Demcizumab | 1243262-17-0 | 98% |
Demcizumab
|
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent Notch pathway inhibitor. Demcizumab is effective in multiple cancer models, bo... | ||||
T76790 | Inotuzumab | 1660159-36-3 | 98% |
Inotuzumab
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22. Inotuzumab is a naked antibody to Inotuzumab ozogamicin and ca... | ||||
T76794 | Ulocuplumab | 1375830-34-4 | 98% |
Ulocuplumab
|
Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma... |